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ABSTRACT
Objective: To study the prevalence, molecular cause, and clinical presentation of hereditary motor
neuropathies in a large cohort of patients from the North of England.
Methods: Detailed neurologic and electrophysiologic assessments and next-generation panel
testing or whole exome sequencing were performed in 105 patients with clinical symptoms of
distal hereditary motor neuropathy (dHMN, 64 patients), axonal motor neuropathy (motor
Charcot-Marie-Tooth disease [CMT2], 16 patients), or complex neurologic disease predominantly
affecting the motor nerves (hereditary motor neuropathy plus, 25 patients).
Results: The prevalence of dHMN is 2.14 affected individuals per 100,000 inhabitants (95%
confidence interval 1.62–2.66) in the North of England. Causative mutations were identified in
26 out of 73 index patients (35.6%). The diagnostic rate in the dHMN subgroup was 32.5%,
which is higher than previously reported (20%). We detected a significant defect of neuromus-
cular transmission in 7 cases and identified potentially causative mutations in 4 patients with
multifocal demyelinating motor neuropathy.
Conclusions: Many of the genes were shared between dHMN and motor CMT2, indicating identical
disease mechanisms; therefore, we suggest changing the classification and including dHMN also as
a subcategory of Charcot-Marie-Tooth disease. Abnormal neuromuscular transmission in some
genetic forms provides a treatable target to develop therapies. Neurology® 2017;88:1226–1234
GLOSSARY
CI 5 confidence interval; CMT 5 Charcot-Marie-Tooth disease; dHMN 5 distal hereditary motor neuropathy; HMN 5 hered-
itary motor neuropathy; LED 5 lower extremity dominance;MAF 5 minor allele frequency; NCS 5 nerve conduction studies;
NGS 5 next-generation sequencing; NMJ 5 neuromuscular junction; SMA 5 spinal muscular atrophy; SMARD1 5 spinal
muscular atrophy with respiratory distress; WES 5 whole exome sequencing.
Distal hereditary motor neuropathies (dHMN) are clinically and genetically heterogeneous dis-
orders caused by lower motor neuron dysfunction.1 The classic phenotype of dHMN is a length-
dependent motor weakness and atrophy, initially affecting the intrinsic foot muscles and the
peroneal compartment of the leg, frequently leading to foot deformities such as pes cavus, pes
planus, and clawing of the toes.2 The majority of the cases show a slowly progressive disease
course gradually involving proximal leg muscles or affecting intrinsic hand muscles. Variable age
at onset, diverse clinical course, and associated neurologic features complicate the pheno-
type and aid the clinical subclassification. Congenital or infantile-onset forms of weakness
and atrophy of the feet and legs with no or very slow disease progression were grouped as
spinal muscular atrophy with lower extremity dominance (SMA-LED). Other clinical
subgroups of dHMN were classified on the basis of additional features such as diaphrag-
matic paralysis (dHMN-IV), upper limb predominance (dHMN-V), SMA with respiratory
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distress (SMARD1 or dHMN-VI), adult-onset
with vocal cord palsy (dHMN-VII), and pyra-
midal features or X-linked inheritance.3
Gene identification in dHMN was previ-
ously based on linkage studies in rare extended
families. However, recent development of
next-generation technology enabled studying
isolated patients or small families, and a large
number of new disease genes and novel pheno-
types have been discovered.4 Compared to the
7 genes and 13 chromosomal loci 10 years
ago,5,6 to date we acknowledge around 30
genes responsible for autosomal dominant,
recessive, and X-linked forms of dHMN. To
identify the molecular cause of motor neurop-
athies, we performed detailed clinical investi-
gations and state of the art genetic studies in
a large, population-based cohort from the
North of England.
METHODS Patients. Between 2010 and 2015, we selected
105 patients out of 461 diagnosed with inherited neuropathies
in our genetic neuropathy clinic at Newcastle Hospitals NHS
Foundation, which is the catchment area of a total population
of 2.99 million. Inclusion of patients was based on the presence
of a motor neuropathy/neuronopathy with no or only subclinical
sensory changes on electrophysiology. Acquired causes were
excluded by detailed laboratory analysis/no response on immuno-
suppressive therapy. Some affected family members of patients
with a confirmed genetic diagnosis were included in this cohort,
even if no electrophysiologic data were available.
Standard protocol approvals, registrations, and patient
consents. Participants provided written informed consent,
approved by local research ethics committees, for all experiments
using human participants and for photographs that may be
published.
Electrophysiology. We performed electrophysiologic examina-
tion in 90 patients according to standard techniques and inter-
preted by the same expert neurophysiologists. Eight family
members did not undergo electrophysiologic studies; 7 patients
were tested at different hospitals. Motor and sensory nerve con-
duction studies (NCS) were performed and qualitative and quan-
titative analysis of motor unit potentials and spontaneous activity
were assessed on EMG. Patient classification into study groups
was based on these analyses. Additional assessment of repetitive
nerve stimulation and single-fiber EMG were carried out in 27
patients, and the percentage increment or decrement was
calculated. EMG was performed using Natus Neurology
(Pleasanton, CA) disposable 30-G concentric needles with
a bandpass range of 10–10,000 Hz. For single-fiber EMG
studies, the low pass filter was increased to 2,000 Hz and the
percentage of fiber pairs showing increased jitter or blocking was
calculated.
Molecular genetic analysis. DNA was obtained from periph-
eral blood. Initially, PMP22 deletion/duplication, MFN2, and
GJB1 were excluded in all patients. The multigene panel assay
utilizing next-generation sequencing (NGS) was carried out in 46
index patients in the Bristol Genetics Laboratory following the
UK Genetic Testing Network approved criteria. Variant
classification was based on Association for Clinical Genetic
Science Practice Guidelines (2013). We performed whole exome
sequencing (WES) in 40 patients. DNA was fragmented, exome-
enriched, and sequenced (Illumina [San Diego, CA] TruSeq 62 Mb
and HiSeq 2000, 100 bp paired-end reads). Bioinformatic analysis
included duplicate sequence read removal with FastUniq,7
alignment to UCSC hg19 with BWA8 variant detection with
FreeBayes, and variant annotation with ANNOVAR. Variants
were annotated as exonic/splicing, excluding synonymous variants,
with a rare minor allele frequency (MAF, 0.01) in the context of
genotype (heterozygous MAF, 0.001; homozygous MAF, 0.01)
in several databases downloaded via ANNOVAR (ExAC,
NHLBI_ESP6500, cg69) and also in 281 in-house exomes.
Protein prediction and evolutionary sequence conservation
algorithms downloaded via ANNOVAR were used to analyze the
in silico effects following the guidelines of the American College of
Medical Genetics and Genomics.9 Variants were defined as
confirmed pathogenic if they were previously shown to be
pathogenic or if they were novel variants in a known neuropathy-
associated gene, predicted to be deleterious (affect protein structure
or function, highly conserved), and segregated with the disease in at
least 1 additional affected family member.10 Highly conserved, in
silico deleterious rare sequence variants of known or novel genes
were determined as possible pathogenic if segregation studies
involving at least one additional affected family member could not
be carried out. Putative pathogenic variants were confirmed by
Sanger sequencing and were tested for segregation.
RESULTS Clinical presentation. We identified 105
patients from 73 families with inherited motor neurop-
athies. Based on neurologic and electrophysiologic
findings, all patients were classified into 1 of 3 sub-
groups: dHMN, motor predominant Charcot-Marie-
Tooth disease (CMT2) (motor CMT2), and motor
neuropathy with additional neurologic symptoms
(hereditary motor neuropathy [HMN] plus).
Diagnosis of dHMN was based on preserved sensory
nerve studies with normal or reduced compound
motor unit action potentials or neurogenic changes
on EMG examination.2 Patients with dHMN but
with decreased sensory nerve action potentials,
indicative of an accompanying sensory axonopathy,
were grouped as motor CMT2. We considered HMN
plus when motor neuropathy was the leading feature,
but was accompanied by other neurologic symptoms.
NCS data of all patients are available on request.
All patients seen in our center were from our
catchment area (2.99 million people in 2011 UK cen-
sus), leading to a minimum prevalence of dHMN as
2.14 affected individuals per 100,000 inhabitants
(95% confidence interval [CI] 1.62–2.66).
Sixty-four out of 105 patients (60.9%) had dHMN.
Sixteen patients had motor CMT2 (15.2%) and 25
HMN plus (23.8%) (figures 1–3). There was male pre-
dominance in all phenotypic groups. Symptoms started
at a younger age in dHMN (mean 16 years) and HMN
plus (mean 17.6 years) compared to motor CMT2
(mean 23.8 years). The main inheritance pattern was
autosomal dominant in CMT2 (7/10 families [70%])
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while isolated cases were more frequent in HMN plus.
The dHMN group consisted of an almost equal num-
ber of dominant families (n5 16) and isolated patients
with negative or unavailable family history (n 5 20).
We identified causative mutations in 26 out of 73
families, providing a 35.6% mutation detection rate
(figure 2). Candidate gene sequencing based on clin-
ical presentation led to the molecular diagnosis in
Figure 1 Clinical heterogeneity of different forms of hereditary motor neuropathy (HMN)
Distal hereditary motor neuropathy (dHMN) (top 2 rows), motor Charcot-Marie-Tooth disease 2 (CMT2) (third row), and HMN plus (bottom row): (A) patients 2
and 3: GARS; (B) patient 19: IGHMBP2; (C) patient 23: TRPV4; (D) patient 32: IGHMBP2; (E) not yet diagnosed dHMN; (F) patient 18: DYNC1H1; (G) patient
10: SYT2; (H) patient 16: BICD2; (I, J) not yet diagnosed spinal muscular atrophy lower extremity dominance; (K) patient 42: AARS; (L) patient 39: AARS; (M)
family 22: DNM2; (N) patient 51: FUS; (O) patient 53: ATP7A; (P) patient 57: TBX5; (Q) patient 58: STAT5B; (R) not yet diagnosed HMN plus.
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5 out of 105 patients only (4.7%), while 12 index
patients were diagnosed by NGS panel from 46 per-
formed tests (26%) and a further 18 index patients
by WES (total 40 analysis) (45%). There were no
novel shared genes/mutations in the exome negative
cases.
Mutation spectrum in dHMN. We achieved the possi-
ble genetic diagnosis in 17/40 families, which re-
sulted in 42.5% detection rate (figure 2). Variants
were considered confirmed pathogenic in 13 index
cases (32.5%); 7 of them carried known pathogenic
dHMN mutations while in 6 families novel delete-
rious variants were detected in known genes and
segregated with the phenotype (table e-1A at
Neurology.org).
A previously reported heterozygous c.421A.G,
p.(Lys141Glu) mutation in HSPB8 presented with
a progressive lower limb predominant phenotype
(family 1). We found 2 novel GARS mutations in 2
independent families (families 2–3). The heterozy-
gous c.647A.G, p.(His216Arg) was detected in
a mother and her son with predominant upper
extremity involvement (dHMN-V) (figure 1A). The
c.1528A.C, p.(Lys510Gln) mutation cosegregated
in 3 generations with dominant distal motor neurop-
athy affecting both upper and lower extremities. Elec-
trophysiologic examination revealed mildly increased
jitter in one patient consistent with a motor neurop-
athy and significantly increased jitter with blocking in
another patient. One patient with dHMN involving
Figure 2 Identified genes in our hereditary motor neuropathy (HMN) patient cohort
(A) Spectrum and distribution of mutated genes detected in our cohort within the 3 phenotypic groups. (B) Overlapping clinical phenotypes related to the
identified genes and key additional clinical features associated. *Upper motor neuron involvement. ALS 5 amyotrophic lateral sclerosis.
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both upper and lower limbs carried the previously
reported c.1834G.A, p.(Val612Met) mutation in
DYNC1H1 (family 7) (figure 1F). A rapidly progres-
sive dHMN in a 15-year-old boy was due to the de
novo previously reported c.1126A.G, p.(Met376V-
al) mutation in MFN2 (family 12).11 The heterozy-
gous c.2119C.T p.(Arg707Trp) MFN2 mutation
was found in a 70- year-old man with late-onset
dHMN (family 13).12
The homozygous frameshift c.292_303delin-
sATGCT p.(Gly98fs) mutation in IGHMBP2 led
to SMARD1 in 2 siblings of consanguineous Pakis-
tani origin (family 8) (figure 1B). A brother and
sister from another family with childhood-onset dis-
tal SMA and lack of respiratory involvement carried
a heterozygous c.1813C.T p.(Arg605*) nonsense
IGHMBP2 mutation, which was hemizygous in the
cDNA (family 9).13
We have previously reported 6 patients with non-
progressive neuropathy and fatigable weakness carrying
c.923C.T; p.(Pro308Leu) in SYT2 (family 4) (figure
1G),14 5 patients with distal congenital nonprogessive
Figure 3 Diagnostic flow chart and mutation detection rates in our hereditary motor neuropathy (HMN) cohort
CMT 5 Charcot-Marie-Tooth disease; dHMN 5 distal hereditary motor neuropathy; WES 5 whole exome sequencing.
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SMA carrying c.320C.T, p.(Ser107Leu) in BICD2
(families 5–6) (figure 1H),15 and 2 patients with
TRPV4 mutations associated with childhood-onset
scapuloperoneal SMA and metatropic dysplasia (family
10) (figure 1C) or adult-onset dHMN (family 11).16
Possibly causative mutations were detected in 4
families (table e-1B). The heterozygous novel
c.2752C . T, p.(Arg918Cys) IGHMBP2 variant
was detected in 3 siblings with motor neuropathy,
without respiratory dysfunction (family 14). All pre-
diction tools predicted this change pathogenic, and it
was absent in the ExAC database, although we could
not identify a second mutation in this family. The
single heterozygous c.767C.G, p.(Ala256Gly)
IGHMBP2 variant was detected in a 3.5-year-old
boy with compatible phenotype (family 15) (figure
1D). In 3 members of a dominant dHMN pedigree
(family 16), we found a novel heterozygous DHTKD1
variant c.628G.T, p.(Ala210Ser). In a young female
patient (family 17) we identified a heterozygous novel
c.1949G.A, p.(Tyr650Cys) sequence change in
ARHGEF10.
Mutation spectrum in motor CMT2.Motor CMT2 was
considered in 16 patients from 10 families. We
achieved 70% mutation detection rate in this group
by concluding molecular diagnosis in 7 CMT2 fam-
ilies (figure 2) (table e-2). We identified the recurrent
c.986G.A, p.(Arg329His) AARS mutation in 6 pa-
tients from 4 families (families 18–21) (figure 1, K
and L).17 In 3 members of a dominant family with
early-onset intermediate motor neuropathy, split
hand deformity, and hearing loss, we detected the
previously described c.1739T.C, p.(Met580Thr)
DNM2 mutation (family 22) (figure 1M).18 A
female patient with upper limb weakness carried the
pathogenic c.1403G.A, p.(Arg468His) MFN2
mutation (family 23).12 Exome sequencing of male
monozygotic twins with early-onset severe motor
predominant neuropathy revealed the recently
reported heterozygous c.754C.T, p.(Arg252Trp)
mutation in the MORC2 gene (family 24).19
Mutation spectrum in HMN plus families. Twenty-five
patients from 23 families with predominant motor neu-
ropathy had additional neurologic features. Confirmed
pathogenic mutations were detected in 6 patients
(26%) and a probable disease cause was identified in a fur-
ther 5 index patients (21.7%) (figure 2, table e-3A). The
heterozygous c.1529A.G p.(Lys510Arg) FUSmutation
was detected in a 52-year-oldmanwith asymmetric lower
limb motor neuropathy. The progression was rapid with
evolving motor neuron disease, frontal dementia, and
loss of ambulation within half a year (family 27) (figure
1N). WES identified a hemizygous c.2279A.G,
p.(Tyr760Cys) novel ATP7A variant with upper
and lower motor neuron symptoms (family 29)
(figure 1O).20 We detected compound heterozygous
c.916G.A, p.(Gly306Arg) and c.1016T.C, p.
(Leu339Pro) mutations in SLC52A2 (family 25)21 and
a homozygous c.96_99dupATCC, p.(Pro34Ilefs*25)
mutation in the c12orf65 gene (family 26).22 Distal
motor neuropathy with ataxia and dystonia was
associated with c.3823C.T p.(Arg1275Cys) in
DCTN1 (family 28).23 Compound heterozygous
c.1580C.G, p.(Ser527*) and c.6781C.A,
p.(Leu2261Ile) mutations in SACS caused juvenile-
onset motor neuropathy, ataxia, and spasticity in a 71-
year-old man (family 30).24 Possibly causative mutations
were detected in 5 families (table e-3B). A 17-year-old
man with distal motor neuropathy and optic atrophy
(CMT type 6) carried a single previously reported
heterozygous c.2386C.T, p.(Gln796*) mutation in
FIG4.25 Heterozygous FIG4 mutations have been
associated with adult-onset amyotrophic lateral sclerosis
but without optic atrophy.26 We found the heterozygous
c.1371C.G, p.(Phe457Leu) mutation in SLC52A3 in
a 19-year-old man with Brown-Vialetto-Van-Laere
syndrome, who responded well to riboflavin therapy.
However, we could not identify a second mutation,
even by analyzing WES for copy number variations
within this gene (family 32). A 19-year-old man with
shoulder girdle weakness commonly seen in Holt-
Oram syndrome carried the previously reported
c.331G.T, p.(Asp111Tyr) TBX5 mutation (family
33, figure 1P).27 We identified the novel homozygous
c.944T.G, p.(Glu315Ala) mutation in the
transcriptional factor STAT5B in a sibling pair from
a consanguineous family with growth retardation,
dysmorphic face, and motor neuropathy (family 34)
(figure 1Q). Asymmetric motor neuron weakness,
cranial nerve involvement, pyramidal signs, and
multifocal motor neuropathy with conduction blocks
were observed in a man who carried a novel de novo
c.269T.C, p.(Phe90Ser) mutation in PTEN (family
35).
DISCUSSION Although HMNs are suggested to be
rare, we identified 105 patients in the North of Eng-
land, with a population of 2.99 million. We previ-
ously determined that the minimum prevalence of
CMT in the North of England is 11.8 per 100,000
individuals.28,29 Here we report that the minimum
prevalence of dHMN in the same population is
2.14 affected individuals per 100,000 inhabitants
(95% CI 1.62–2.66), which is higher than suggested
earlier.29,30
Previous studies indicated that the molecular cause
can be identified in the vast majority of patients with
demyelinating CMT; however, the detection rate has
been much lower in dHMN and motor CMT2
(;20).3 We identified potentially pathogenic muta-
tions in 47.9% (35/73 families), which consisted of
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confirmed mutations in 35.6% and possibly causative
variants in an additional 12.3%. Previously in
dHMN, the detection rate was 15%–20%.3,5,6,31
We confirmed genetic diagnosis in 32.5% (13/40
families) of dHMN, and a likely causative mutation
was identified in an additional 10% (figure 2), which
is higher than in previous studies (tables e-4–e-6).
dHMN is strictly considered as the pure motor
end of CMT, many patients show minor sensory
abnormalities,1,6 and mutations in the same gene
can cause both dHMN and CMT2.2,31 HMN may
be complicated by SMA, spastic paraplegia, or other
neurologic abnormalities.1,6,32 Affected pathways
linked to dHMN include DNA/RNA metabolism,
protein translation and synthesis, stress response, apo-
ptosis, axonal guidance, intracellular trafficking,
and synaptic activity (figure 4). Mitochondrial abnor-
malities are common in our cohort in all forms of
motor neuropathies and contribute to the symp-
toms by altering mitochondrial fusion/fission
(MFN2, DNM2, SLC25A46), axonal transport
(HSPB1, HSPB8), protein synthesis (C12orf65,
SACS), or cofactors (SLC52A2/3).
SMA-LED has been introduced to characterize the
congenital or early childhood-onset nonprogressive
atrophy and weakness of the legs affecting both distal
and proximal muscles, caused by altered motor neuron
development or function.3 The clinical presentation
may overlap between spinal and distal motor neuron
dysfunction. Correction of deformities is important,
since these patients do not deteriorate in the later dis-
ease course. We identified 17 patients with clinical
symptoms resembling SMA-LED, carrying mutations
in SYT2, BICD2, and DYNC1H1, and no causative
mutation was identified in 4 patients (figure 1, I–J).
No major common pathway can be highlighted by the
pathomechanism of these genes, while different muta-
tions in the same gene (such as DYNC1H1) may also
cause different clinical presentations.
We reported that mutations in synaptic proteins
can cause nonprogressive motor neuropathy and fati-
gable weakness with presynaptic neuromuscular junc-
tion (NMJ) defect (SYT2),15 which can benefit from
3,4 diaminopyridine treatment.33 Abnormal neuro-
muscular transmission has been shown in Drosophila
and mouse models of GARS mutations.34,35 Further-
more, a genetic defect of the presynaptic choline
transport leads to HMN due to SLC5A7mutations.36
Based on these findings, we studied neuromuscular
transmission in 27 patients and substantial abnormal-
ities (over and above that expected in the context of
immature NMJs formed during denervation and re-
innervation) were detected in 7 cases harboring dif-
ferent gene mutations. Further detailed studies of the
NMJ are warranted, including genetically character-
ized patients. Neuromuscular transmission can be
Figure 4 Pathomechanisms of genes reported in hereditary motor neuropathy (HMN)
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modified by several, already available compounds,
which have been broadly used in congenital myas-
thenic syndromes, but not in hereditary neuropathies.
We suggest performing repetitive stimulation and sin-
gle fiber EMG as part of routine electrophysiologic
studies in patients with HMN in order to uncover
potentially treatable transmission defects.
We identified a subgroup of patients with inherited
motor neuropathy, resembling multifocal demyelinat-
ing motor neuropathy or nodo-paranodopathy. Talipes
and pure motor nerve involvement were caused by
a novel mutation in ARHGEF10. Slow nerve conduc-
tion velocities have been implicated in ARHGEF10
mutations and a 10-bp deletion in Leonberger dogs
led to pelvic muscle weakness, stepping gait, and recur-
rent laryngeal nerve palsy.37
A previously reported pathogenic mutation in
TBX5 was detected in a patient with demyelinating
multifocal motor neuropathy. TBX5 participates in
transcriptional regulatory cascades and its pathogenic
mutations, located within the DNA binding T-box
domain, manifest in a rare condition called Holt-
Oram syndrome with deformity of upper limbs, carpal
tunnel syndrome, and cardiac anomalies.27 We suggest
thatTBX5may cause demyelinating neuropathy affect-
ing predominantly the motor nerves. No cardiac symp-
toms were detected in our patient. We detected a novel
possibly causative STAT5B mutation in a sibling pair
with motor neuropathy, ptosis, short stature, and dys-
morphic facial features. Homozygous mutations in
STAT5B, a signal transducer and activator of transcrip-
tion, have been reported in only a handful of patients
worldwide, all manifesting with postnatal growth retar-
dation and occasional immunologic alterations.38
Impaired STAT5B signaling may lead to aberrant
peripheral myelination through cyclin D1 overexpres-
sion and may have an effect on neuronal growth and
differentiation.39 Finally, we detected a possibly causa-
tive de novo PTEN mutation in a patient with patchy
motor neuropathy, focal demyelination, hamartoma-
like skin lesions, and autism spectrum disorder. PTEN,
a lipid phosphatase, inhibits phosphoinositide 3-
kinase, which is also impaired in several forms of
CMT (FIG4, FGD4, MTMR2, MTMR13/SBF2). It
has been implicated in peripheral neural plasticity, axo-
nal outgrowth, and hypermyelination. Experimental
PTEN suppression in mice resulted in progressive
peripheral neuropathy with tomacula formation and
myelin outfoldings.40
The identification of pathogenic mutations in the
same genes in dHMN and motor CMT indicate that
dHMN should not be classified as a different disease
group. The detection of mutations in rare disease
genes, not implicated in neuropathy to date, suggest
that the neuropathy can be part of a more complex
genetic disease and key clinical signs are important
to recognize these diseases. These overlapping pheno-
types highlight basic biological pathways in peripheral
nerves that may be targeted to develop therapies for
patients with inherited motor neuropathies.
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